Nicotine replacement therapy: An overview

International Journal of Health Science

Volumn 10, Issue 3, 2016, Pages 425-435

  Wadgave, Umesh ^a   Nagesh, L ^b  

^a Bharati Vidyapeeth Deemed University Dental College and Hospital   (India)

^b INSTITUTE OF DENTAL SCIENCES   (India)

Author keywords

Nicotine and therapy

Indexed keywords

EID: 85029364773     PISSN: 17914299     EISSN: 17914728     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Foulds J, Burke M, Steinberg M, Williams JM, Ziedonis DM. Advancesin pharmacotherapy for tobacco dependence. Expert OpinEmerg Drugs. 2004; 9(1): 39-53.
2. Kotlyar M, Hatsukami DK. Managing nicotine addiction. J Dent Educ. 2002 Sep; 66(9): 1061-73.
3. Scherer G. Smoking behavior and compensation: a review of the literature. Psychopharmacology (Berl)1999; 145(1): 1-20.
4. Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens. Nicotine Tob Res. 2004; 6(6): 899-912.
5. Garret BE, Rose CA, Hennigfield JE. Tobacco addiction and pharmacological interventions. Expert OpinPharmacother. 2001; 2(10): 1545-1555
6. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev PharmacolToxicol. 2009; 49: 57-71.
7. Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens. Nicotine Tob Res. 2004; 6(6): 899-912.
8. Centers for Disease Control and Prevention (US), National Center for Chronic Disease Prevention and Health Promotion (US), Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2010. Available from: http: //www. ncbi. nlm. nih. gov/books/NBK53 018/
9. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004; (3): CD000146. Review. Update in: Cochrane Database Syst Rev. 2008; (1): CD000146.
10. Le Foll B, Melihan-Cheinin P, Rostoker G, Lagrue G. Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency. European Psychiatry 2005; 20: 431-4.
11. Yildiz D. Nicotine, its metabolism and an overview of its biological effects. Toxicon. 2004; 43(6): 619-632.
12. Molyneux A, Králíková E, Himmerová V. ABC of smoking cessation. Nicotine replacement therapy. CasLekCesk. 2004; 143(11): 781-3.
13. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA. 2000 Jun 28; 283(24): 3244-54. Review.
14. Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. 2005 Sep-Oct; 55(5): 281-99.
15. Sweeney CT, Fant RV, Fagerstrom KO, McGovern JF, Henningfield JE. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs 2001; 15: 453-67.
16. Fagerstrom KO. Combined use of nicotine replacement products. Health Values 1994; 18: 15-20.
17. Prochaska JJ. Nicotine Replacement Therapy as a Maintenance Treatment. JAMA. 2015 Aug 18; 314(7): 718-9.
18. Hajek P, Stead LF. Aversive smoking for smoking cessation. Cochrane Database Syst Rev. 2000; (2): CD000546.
19. D'Souza MS, Markou A. Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict SciClinPract. 2011 Jul; 6(1): 4-16.
20. Shiffman S, Rolf CN, HellebuschSJ, Gorsline J, Gorodetzky CW, Chiang YK, et al. Real-world efficacy of prescription and over-the counter nicotine replacement therapy. Addiction 2002; 97: 505-16
21. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med. 1995 Nov 2; 333(18): 1196-203.
22. Molander L, Lunell E. Pharmacokinetic investigation of a nicotine sublingual tablet. Eur J ClinPharmacol. 2001 Jan-Feb; 56(11): 813-19.
23. Choi JH, Dresler CM, Norton MR, Strahs KR. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res. 2003 Oct; 5(5): 635-44.
24. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U. S. Public Health Service report. Am J Prev Med. 2008 Aug; 35(2): 158-76.
25. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med. 1995 Nov 2; 333(18): 1196-203.
26. Hajek P, Etter JF, Benowitz N, Eissenberg T, McRobbie H. Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction. 2014 Nov; 109(11): 1801-10.
27. Cantrell FL. Adverse effects of e-cigarette exposures. Journal of community health. 2014-Jun 2014; 39(3): 614-16.
28. Brokowski L, Chen J, Tanner S. High-dose transdermal nicotine replacement for tobacco cessation. Am J Health Syst Pharm. 2014 Apr 15; 71(8): 634-8.
29. Recommendations for Use of Combination Therapy in Tobacco Use Cessation [cited 2016 Januray 03]. Available from: http: //www. healthquality. va. gov/guidel ines/CD/mtu/tuc_combination_therapy. pdf
30. U. S. Department of Veteran affairs [cited 2015 october 15] Available from: https: //www. myhealth. va. gov/mhvportalweb/ anonymous. portal?_nfpb=true& _nfto=false&_pageLabel=spotlightArchive &contentPage=spotlight/November%2020 11/spotlight_nov2011_smoking. html
31. Seigel MB, Tanwar KL, Wood KS. Electronic cigarettes as a smokingcessation tool: results from an online survey. Am J Prev Med2011; 40: 472-5.
32. International Union against Tuberculosis and Lung diseases [cited 2016 January 04] Available from: file: ///C: /Users/Client/Downloads/Ecigarette_ statement_FULL. pdf
33. Goniewicz ML, Kuma T, GawronM, Knysak J, Kosmider L. Nicotine levels in electronic cigarettes. Nicotine Tob Res2013; 15: 158-66.
34. Palazzolo DL. Electronic cigarettes and vaping: a new challenge in clinical medicine and public health. A literature review. Front Public Health. 2013 Nov 18; 1: 56.
35. Jerry JM, Collins GB, Streem D. Ecigarettes: Safe to recommend to patients? Cleve Clin J Med. 2015 Aug; 82(8): 521-6.
36. Lam C, West A. Are electronic nicotine delivery systems an effective smoking cessation tool? Can J RespirTher. 2015 Fall; 51(4): 93-8.
37. McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev. 2014; 12: CD010216.
38. Hurt RD, Dale LC, Offord KP, Lauger GG, Baskin LB, Lawson GM, et al. Serum nicotine and cotinine levels during nicotinepatch therapy. ClinPharmacolTher. 1993; 54: 98-106.
39. Schnoll RA, Wileyto EP, Leone FT, Tyndale RF, Benowitz NL. High dose transdermal nicotine for fast metabolizers of nicotine: a proof of concept placebocontrolled trial. Nicotine Tob Res. 2013; 15: 348-54.
40. Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE et al. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res. 1999; 1: 169-74.
41. Ebbert JO, Dale LC, Patten CA. Croghan IT, Schroeder DR, Moyer TP, et al. Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users. Nicotine Tob Res. 2007; 9: 43-52.
42. Shiffman S, Cone EJ, Buchhalter AR, Henningfield JE, Rohay JM, Gitchell JG et al. Rapid absorption of nicotine from new nicotine gum formulations. PharmacolBiochemBehav. 2009 Jan; 91(3): 380-4.
43. Niaura R, Sayette M, Shiffman S, Glover ED, Nides M, Shelanski M, et al. Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction. 2005 Nov; 100(11): 1720-30.
44. Fagerstrom KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology 1993; 111: 271-277.
45. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 1995; 24: 41-47.
46. Puska P, Korhonen H, Vartiainen E, E. L. Urjanheimo, G. Gustavsson, A. Westin. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tob Control 1995; 4: 231-235.
47. Shah SD, Wilken LA, Winkler SR, lin S-J. Systematic review and meta-analysis of combination therapy for smoking cessation. J Am Pharm Assoc 2008; 48: 659-65.
48. Fagerström K., Hughes J. Nicotine concentrations with concurrent use of cigarettes and nicotine replacement. Nicotine Tob Res2002; 4: 73-9.
49. Rose J. E., Behm F. M., Westman E. C. Nicotine-mecamylamine treatment for smoking cessation: the role of precessation therapy. ExpClin Psychopharmacol1998; 6: 331-43
50. Stead L. F., Perera R., Bullen C., Mant D., Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev2008; 1: CD000146.
51. Bullen C, Howe C, Lin RB, Grigg M, Laugesen M, McRobbie H, et al. Precessation nicotine replacement therapy: pragmatic randomized trial. Addiction. 2010 Aug; 105(8): 1474-83.
52. Carrera, M. R., Ashley, J. A., Hoffman, T. Z., Isomura, S., Wirsching, P., Koob, G. F. et al. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorganic & Medicinal Chemistry, 2004; 12(3): 563-70.
53. Harmey D, Griffin PR, Kenny PJ. Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions. Nicotine Tob Res. 2012 Nov; 14(11): 1300-18.
54. Scherer, G. Smoking behaviour and compensation: a review of the literature. Psychopharmacology, 1999; 145(1): 1-20.
55. Hartmann-Boyce J, Cahill K, Hatsukami D, Cornuz J. Nicotine vaccines forsmoking cessation. Cochrane Database Syst Rev. 2012 Aug 15; 8: CD007072.
56. Nabi Biopharmaceuticals Announces Results of Second NicVAX(R) Phase III Clinical Trial. Available From: http: //globenewswire. com/newsrelease/ 2011/11/07/460749/237357/en/Na bi-Biopharmaceuticals-Announces-Results-of-Second-NicVAX-R-Phase-IIIClinical-Trial. html
57. Shen XY, Orson FM, Kosten TR. Vaccines against drug abuse. ClinPharmacolTher. 2012 Jan; 91(1): 60-70.
58. Shen X, Orson FM, Kosten TR. Antiaddiction vaccines. F1000 Med Rep. 2011; 3: 20.
59. Meyer, B. How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self experiments in the nineteenth century. Arch Toxicol. 2014 Jan; 88(1): 5-7.
60. Karl Fagerström. Nicotine: Pharmacology, Toxicity and Therapeutic use. J SmokCessat. 2014; 9: 53-59.
61. Lavelle C, Birek C, Scott DA. Are nicotine replacement strategies to facilitate smoking cessation safe? J Can Dent Assoc. 2003 Oct; 69(9): 592-7.
62. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ. 2009 Apr 2; 338: b1024.
63. Osadchy A, Kazmin A, Koren G. Nicotine replacement therapy during pregnancy: recommended or not recommended? J ObstetGynaecol Can. 2009 Aug; 31(8): 744-7
64. Cooper S, Lewis S, Thornton JG, Marlow N, Watts K, Britton J, et al. Smoking, Nicotine and Pregnancy Trial Team. The SNAP trial: a randomized placebocontrolled trial of nicotine replacement therapy in pregnancy-clinical effectiveness and safety until 2 years after delivery, with economic evaluation. Health Technol Assess. 2014 Aug; 18(54): 1-128.
65. Mendelsohn C. Optimising nicotine replacement therapy in clinical practice. AustFam Physician. 2013 May; 42(5): 305-9.
66. Shiffman S, Ferguson SG, Rohay J, Gitchell JG. Perceived safety and efficacy of nicotine replacement therapies among uS smokers and ex-smokers: relationship with use and compliance. Addiction 2008; 103: 1371-8.
67. Ferguson SG, Gitchell JG, Shiffman S, Sembower MA, Rohay JM, Allen J. Providing accurate safety information may increase a smoker's willingness to use nicotine replacement therapy as part of a quit attempt. Addict Behav 2011; 36: 713-6.
68. Yingst JM, Veldheer S, Hrabovsky S, Sciamanna C, Foulds J. Reasons for nonadherence to nicotine patch therapy during the first month of a quit attempt. Int J ClinPract. 2015 Aug; 69(8): 883-8.
69. Hughes JR. Use of nicotine replacement after a smoking lapse. Nicotine Tob Res 2012; 14: 751-4.
70. Balmford J, Borland R, Hammond D, Cummings KM. Adherence to and reasons for premature discontinuation from stopsmoking medications: data from the ITC four-country survey. Nicotine Tob Res 2011; 13: 94-102.
71. K. O. Fagerstrom and C. A. Jimenez-Ruiz. Pharmacological treatments for tobacco dependence. European Respiratory 2008; 17(110): 192-8.